A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the drug continuously for about a year and 4 months and then stopping. It found that about two-thirds regained the weight they lost. A similarly designed study had comparable results for tirzepatide (Zepbound).

Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel full. When the drug interacts with a receptor in the stomach, patients feel full sooner and for a longer period of time after eating. The drug does not cause weight loss directly – instead, it makes you want to eat less.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.

Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday on Capitol Hill.

The term "Ozempic face" is not a medical term, but some use it to describe this type of appearance after weight loss. Here what's fact and fiction.